血清AIF、SF、AFP、CEA RIA在原发性肝癌及肺癌诊断中的临床价值

THE CLINICAL VALUE OF SERUM AIF, SF,AFP AND CEA RIA IN DIAGNOSIS OF PRIMARY HEPATIC CARCINOMA AND PULMONARY CARCINOMA

本文检测85例原发性肝癌患者AFP、AIF、SF阳性率依次为84.7％、76.5％、54.1,AFP与AIF或SF联检可使阳性率分别提高至97.6％、94.1％。在AFP阴性或低浓度时,AIF与SF联检可弥补AFP之不足。测定36例肺癌患者CEA、AIF、SF阳性率分别为72.2％、77.8％、72.2％,三项指标联检阳性率可达100％。由此说明多项标志物联检对提高恶性肿瘤诊断的阳性率和特异性具有重要临床价值。

Serum AFP, AIF and SF were determined in 85 caces of primary hepatic carcinoma,the positive rate being 84.7%, 76.5% and 54.1% respectively. Combined determination of AFP with ATF or SF could increase the positive rate to 97.6% and 94.1% respectively In cases with negative or very low levels of serum AFP,Combined determination of AIF and SF sometimes could make it up.In 36 caces of pulmonary carcinoma, the positive rate for CEA, AIF, SF was 72.2%, 77.8% and 72.7% respectively. Combined determination of those three could reach a positive rate of 100%.It seems that combined determination of multiple markers is of important clinical value in establishing a diagnosis.